IMPower133 study
The IMpower133 study has brought significant advancements in the treatment of advanced-stage small-cell lung cancer (ES-SCLC). By combining atezolizumab, a type of immunotherapy, wit...
extensive-stage-small-cell-lung-cancer
May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung cancer (ES-SCLC) in patients wh...
extensive-stage-small-cell-lung-cancer